| 引用本文： |
-
丁菊蓉,倪健.晚期非小细胞肺癌二线靶向治疗失败后不同治疗方案的比较[J].同济大学学报（医学版）,2013,34(6):67-70. [点击复制]
- DING Ju-rong1,N1 Jan.Comparison of therapeutic regimens in patients with advanced non-small cell lung cancer after failed second-line targeting therapy[J].同济大学学报（医学版）,2013,34(6):67-70. [点击复制]
|
|
| 摘要: |
| 目的回顾性分析晚期非小细胞肺癌（NSCLC）在二线表皮生长因子受体酪氨酸激酶抑制剂（EGFR—TKI）治疗失败后接受不同治疗方案对无进展生存期及生存时间的关系。方法收集我院2007年1月1日-2012年5月1日具有明确细胞或组织学类型，临床分期为ⅢB或Ⅳ期的NSCLC患者120例，且明确接受过二线靶向治疗后经证实疾病进展的相关临床资料。结果120例患者EGFR—TKI治疗经证实失败后，分别接受了最佳支持治疗（BSC），单药化疗以及含铂方案的两药联合化疗，对其基本情况进行分析，显示不同方案的无进展生存期（Progression—Free Survival，PFS）和整体生存期（Overall Survival，OS）与性别、年龄无关；化疗，尤其是含铂方案的联合化疗能明显提高其疾病无进展期及生存时间，P均〈0．05，差异具有统计学意义。结论晚期NSCLC患者在靶向治疗失败后，化疗，尤其是含铂方案的联合化疗能明显提高患者的PFS及生存时间。 |
| 关键词: 非小细胞肺肿瘤 表皮生长因子受体酪氨酸激酶抑制剂 疾病控制率 生存时间 无进展生存期 |
| DOI：10. 3969/j. issn1008-0392. 2013. 06. 015 |
|
| 基金项目: |
|
| Comparison of therapeutic regimens in patients with advanced non-small cell lung cancer after failed second-line targeting therapy |
| DING Ju-rong1,N1 Jan |
| (Dept. of Emergency, Pulmonary Hospital, Tongji University, Shanghai 200433, China;Dept. of Oncology, Pulmonary Hospital, Tongji University, Shanghai 200433, China)) |
| Abstract: |
| Objective To compare different therapeutic regimens in patients with advanced non-small-cell lung cancer （NSCL） after failed second-line molecular targeting therapy. Methods One hundred and twenty patients with advanced NSCLC were admitted from January 2007 to May 2012. Results After the failure of EGFR-TKI targeting therapy patients received best supporting care （BSC, n = 28 ） , monochemotherapy （ n = 38 ） or platinum-doublet chemotherapy （ n = 54 ）. Progression-free survival （PFS）and overall survival （OS）were retrospectively analyzed in three groups. Both the OS and PFS in patients treated with platinum-based combined chemotherapy were longer than those treated with BSC and monochemotherapy （ P 〈 0. 05 ）. Conclusion Platinum-based combined chemotherapy may improve the survival of advanced NSCL patients after failed molecular targeting therapy. |
| Key words: non-small cell lung cancer disease control rate EGFR-TKI survival progression-free survival |
